Whatever happens with Avastin, NVS is still very happy to have inked a deal for the ex-US commercial rights to Lucentis. It sure beats trying to sell Visudyne.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”